Survival and safety analysis of COVID-19 vaccine in Chinese patients with non-small cell lung cancer

Area of Science:

• Oncology
• Immunology
• Infectious Diseases

Background:

• The COVID-19 pandemic posed significant risks to cancer patients.
• Non-Small Cell Lung Cancer (NSCLC) patients are a vulnerable population during pandemics.
• Assessing vaccine safety and efficacy in NSCLC patients is crucial.

Purpose of the Study:

• To evaluate the safety of COVID-19 vaccines in NSCLC patients.
• To determine the efficacy of COVID-19 vaccines in NSCLC patients.
• To analyze the impact of vaccination on survival outcomes in NSCLC patients.

Main Methods:

• Patient-reported adverse events were collected via questionnaires.
• Survival analysis utilized the Kaplan-Meier method.
• Cox proportional hazard regression models assessed factors influencing survival.

Main Results:

• 860 NSCLC patients were enrolled; 71.11% of early-stage and 19.48% of advanced-stage patients were vaccinated.
• The most common adverse reaction was weakness; concerns about vaccine safety during treatment were primary refusal reasons.
• Vaccination did not significantly impact disease-free survival, progression-free survival, or overall survival in NSCLC patients.

Conclusions:

• COVID-19 vaccination is safe for Chinese NSCLC patients receiving antitumor treatments.
• Vaccination does not increase adverse reaction incidence in NSCLC patients.
• COVID-19 vaccination does not negatively affect cancer patient survival outcomes.